Sector: Health Care
Director information for RECURSION PHARMACEUTICALS INC CLAS (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Blake Borgeson, Ph.D. | Director | 44 | ["Co-founder of the Company","Chief Technical Officer from November 2013 to July 2018","B.S. in electrical engineering from Rice University","Worked as a software research intern at M.E. Mueller Institute","Co-founded an e-commerce company, BuildASign.com","Ph.D. in biology for bioinformatics work at UT Austin","Served on the board of the Machine Intelligence Research Institute since September 2018"] | ["Audit","Nominating and Corporate Governance","Technology","Corporate Social Responsibility"] | 2026 |
| Christopher Gibson, Ph.D. | Chair of the Board | 43 | ["Co-founder of the Company","Former Chief Executive Officer","M.D./Ph.D. student at the University of Utah","Undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) from Rice University","Board member of Pacific Biosciences of California, Inc.","Board member of Cellino","Adviser to young biotechnology founders","Board member of the Salt Lake Tribune","Co-author of peer-reviewed studies in various journals"] | ["Research and Development","Technology","Corporate Social Responsibility"] | 2026 |
| Dean Y. Li, M.D., Ph.D. | Executive Vice President and President, Merck Research Laboratories | 64 | ["Co-founder of the Company","Executive Vice President and President, Merck Research Laboratories since January 2021","Senior Vice President of Discovery Sciences and Translational Medicine, Merck Research Laboratories","Vice President and Head of Translational Medicine at Merck","Conducted medical research at the University of Utah","Co-founded multiple biotech companies","H.A. & Edna Benning Professor of Medicine and Cardiology","Vice-dean of research at the University of Utah Health Science Center","Chief scientific officer of University of Utah Health Care","Interim chief executive officer of Associated Regional University Pathologists","Trained at Washington University in Saint Louis"] | ["Research and Development"] | 2026 |
| Elaine Sun, M.B.A. | Director | 55 | ["Chief Financial Officer and Chief Operating Officer of Mammoth Biosciences, Inc.","Senior Vice President and Chief Financial Officer of Halozyme Therapeutics, Inc.","Chief Financial Officer and Chief Strategy Officer at SutroVax, Inc.","Managing Director and Head of West Coast Healthcare for Evercore Partners","Managing Director at Merrill Lynch & Co., Inc.","Board member of Dynavax Technologies Corporation"] | ["Audit","Compensation"] | 2026 |
| Franziska Michor, Ph.D. | Director | 43 | ["Charles A. Dana Chair in Human Cancer Genetics at the Dana-Farber Cancer Institute","Professor of Computational Biology and of Stem Cell and Regenerative Biology at Harvard University","Ph.D. in Organismic and Evolutionary Biology from Harvard University","Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center","Director of the Dana-Farber Cancer Institute Center for Cancer Evolution","Recipient of the Theodosius Dobzhansky Prize","Recipient of the Alice Hamilton Award","Recipient of the Vilcek Prize for Creative Promise in Biomedical Science","Recipient of the 36th Annual AACR Award for Outstanding Achievement in Cancer Research"] | ["Research and Development","Technology"] | 2026 |
| Najat Khan, Ph.D. | Chief Executive Officer and President | 42 | ["Chief Research and Development Officer","Chief Commercial Officer","Chief Data Science Officer","Senior Vice President/Global Head, Strategy and Portfolio Organization, R&D","Senior Vice President/Global Head, Strategy and Operations, R&D","Chief Operating Officer, R&D Data Science","Head of R&D Strategic Initiatives","Co-chair of Data Science Council at Johnson and Johnson","Partner within the Healthcare Practice at The Boston Consulting Group","Ph.D. in Organic Chemistry","B.S. in Computational Chemistry"] | ["Strategic Transactions and Finance"] | 2026 |
| Namandjé Bumpus, Ph.D. | Chief Scientific and Innovation Officer | 45 | ["Chief Scientific and Innovation Officer of Charles River Laboratories","Former FDA Principal Deputy Commissioner","Research expertise in pharmacology, pharmacogenetics, and bioanalytical chemistry","E.K. Marshall and Thomas H. Maren Professor and chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University","Associate dean for basic research at Johns Hopkins","Elected fellow of the American Association for the Advancement of Science","Member of the National Academy of Medicine"] | ["Nominating and Corporate Governance","Research and Development","Technology"] | 2026 |
| Robert Hershberg, M.D., Ph.D. | Director | 63 | ["Ph.D. in biology from the University of California, San Diego","M.D. from the University of California, Los Angeles","B.A. from the University of California, Los Angeles","Senior management experience in the pharmaceutical industry","Scientific background"] | ["Compensation","Research and Development","Strategic Transactions and Finance"] | 2026 |
| Zachary Bogue, J.D. | Board Member | 50 | ["Over two decades of experience in Silicon Valley","Entrepreneur","Venture capitalist","Attorney","Angel investor","Co-founded DCVC","Investments in Freenome, Relation Therapeutics, Planet Labs, Tala, Oklo, CH4 Global, Insight M","Entrepreneur with three founded companies","Early investments in Block and Uber Technologies","Young Global Leader by World Economic Forum"] | ["Compensation","Corporate Social Responsibility"] | 2026 |
| Zavain Dar | Director; Chair; Founder and Managing Partner | 37 | ["Founder and Managing Partner of Dimension","General Partner at Lux Capital","Experience in machine learning and AI","Background in technology and life science investments","B.S. in Symbolic Systems from Stanford University","M.S. in Theoretical Computer Science from Stanford University","Researcher and Lecturer in Stanford’s AI Lab"] | ["Audit","R&D","Technology","SocialResponsibility","Nominating and Corporate Governance","Strategic Transactions and Finance","Corporate Social Responsibility","Strategic Transaction and Finance"] | 2026 |
